Vivos Therapeutics (VVOS) Proxy Filing summary

Executive summary

• The 2024 Annual Meeting will be held virtually on November 26, 2024, with voting available online, by mail, or by fax.

• Stockholders will vote on the election of six directors, approval of the 2024 Omnibus Equity Incentive Plan, and ratification of Moss Adams LLP as the independent auditor.

• The Board recommends voting FOR all director nominees and FOR all proposals.

• Only stockholders of record as of October 4, 2024, are entitled to vote.

Voting matters and shareholder proposals

• Proposals include: election of six directors, approval of the 2024 Omnibus Equity Incentive Plan, and ratification of Moss Adams LLP as auditor.

• The 2024 Omnibus Plan will replace the 2019 Plan, with 1,600,000 shares reserved for future awards.

• Stockholders may submit proposals for the 2025 meeting by September 27, 2024, for inclusion in proxy materials.

• Proxy voting is encouraged to ensure quorum and representation.

Board of directors and corporate governance

• The Board consists of six members, five of whom are independent under Nasdaq rules.

• Committees include Audit, Compensation, and Nominating and Corporate Governance, all with independent directors.

• The Board met eight times in 2023, with high attendance rates.

• Board diversity includes one female and five male directors, with varied professional backgrounds.